Search

Agios Pharmaceuticals Inc

Открыт

СекторЗдравоохранение

33.39 -0.12

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

32.22

Макс.

33.83

Ключевые показатели

By Trading Economics

Доход

-1.6M

-101M

Продажи

24M

45M

Прибыль на акцию

-1.69

Рентабельность продаж

-225.06

Сотрудники

539

EBITDA

-11M

-109M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+23.48% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-253M

1.9B

Предыдущая цена открытия

33.51

Предыдущая цена закрытия

33.39

Новостные настроения

By Acuity

34%

66%

104 / 340 Рейтинг в Healthcare

Agios Pharmaceuticals Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

12 авг. 2026 г., 20:01 UTC

Agios Pharmaceuticals Inc shares are higher today amid unusually high trading volume. The stock has gained significantly since Tuesday's close.

11 авг. 2026 г., 19:26 UTC

Agios Pharmaceuticals Inc shares are higher today, with no specific news driving the move. Market focus remains on upcoming U.S. inflation reports.

10 авг. 2026 г., 21:01 UTC

Agios Pharmaceuticals Inc shares are lower in after-market trading, with no specific news identified to explain the decline. The stock remains below its 20-day moving average.

6 авг. 2026 г., 19:32 UTC

Agios Pharmaceuticals shares are higher today, continuing an upward trend since Wednesday. The stock peaked earlier in the session before a slight pullback.

5 авг. 2026 г., 19:56 UTC

News

Agios Pharmaceuticals is under investigation regarding its decision on tebapivat, contributing to lower trading activity today amid ongoing investor concerns.

4 авг. 2026 г., 20:02 UTC

Agios Pharmaceuticals Inc shares are higher today amid broader market gains, supported by falling crude oil prices and comments on potential peace talks with Iran.

3 авг. 2026 г., 20:06 UTC

Agios Pharmaceuticals Inc shares are higher today, continuing an upward trend since Friday's close. No specific news was identified to explain the movement.

31 июл. 2026 г., 22:51 UTC

Agios Pharmaceuticals Inc. shares are lower in after-market hours, reflecting broader market declines amid mixed tech earnings and rising U.S. Treasury yields.

30 июл. 2026 г., 20:08 UTC

Agios Pharmaceuticals shares are lower today amid mixed economic signals and unusually high trading volume. The stock has declined since Wednesday's close.

29 июл. 2026 г., 20:51 UTC

Agios Pharmaceuticals Inc shares gained in after-market trading, rebounding from a session low despite broader market pressures from rising crude oil prices and geopolitical tensions.

28 июл. 2026 г., 20:02 UTC

News

Agios Pharmaceuticals shares are lower amid an investigation into potential claims following the halted development of tebapivat for sickle cell disease.

27 июл. 2026 г., 20:01 UTC

Agios Pharmaceuticals Inc shares are higher during Monday's session, reaching a notable peak earlier in the day. No specific news was identified for the move.

24 июл. 2026 г., 23:21 UTC

Agios Pharmaceuticals shares are higher in after-market trading, supported by a decline in initial jobless claims, indicating a robust labor market.

22 июл. 2026 г., 22:41 UTC

Agios Pharmaceuticals shares are lower in after-market trading, continuing a three-session decline amid broader market concerns over rising crude oil prices and inflation.

21 июл. 2026 г., 19:01 UTC

News
Event
Social Media

Agios Pharmaceuticals shares declined after discontinuing tebapivat development for sickle cell disease, despite some trial improvements. The stock remains lower since Monday's close.

Сравнение c конкурентами

Изменение цены

Agios Pharmaceuticals Inc Прогноз

Целевая цена

By TipRanks

23.48% рост

Прогноз на 12 месяцев

Средняя 41.33 USD  23.48%

Максимум 55 USD

Минимум 31 USD

Основано на мнении 9 аналитиков Wall Street, спрогнозировавших целевые цены для Agios Pharmaceuticals Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

9 ratings

6

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

104 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Agios Pharmaceuticals Inc

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat